U.S. Markets closed

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
55.11-0.79 (-1.41%)
At close: 2:57PM EDT
Sign in to post a message.
  • a
    ash
    IBD says the stock is “popping “ on MM news. The only thing that’s popping are the champagne corks of short sellers. I think WS has given up on BLUE.
  • Y
    YR
    Article 30 of the European Economic Community (EEC) Treaty states that anti-competitive behavior and violation of IP is a reason to restrict commercialization of a product in the European Member States.
  • M
    Max
    I'm pretty sure BLUE is the only company to get approval for treatment then not make a single sale. Maybe approval in the US next spring (assuming that happens) will be the catalyst to finally generating some sales.

    What a weird company.
  • B
    Bee
    Bluebird bio's (NASDAQ:BLUE) LentiGlobin, an investigational gene therapy (bb1111) for the treatment of sickle cell disease (SCD), has been granted PRIME status in Europe.PRIME, akin to Breakthrough Therapy status in the U.S., provides for mo
    Bluebird bio's (NASDAQ:BLUE) LentiGlobin, an investigational gene therapy (bb1111) for the treatment of sickle cell disease (SCD), has been granted PRIME status in Europe.PRIME, akin to Breakthrough Therapy status in the U.S., provides for mo
    seekingalpha.com
  • a
    ash
    The problem with BLUE is not it’s management. It’s the product. The only approved indication of this drug is for thalassemia patients who cannot get a matching donor for a stem cell transplant. It requires a month or so of intensive care and highly trained ( expensive) staff. Which is. Why it costs $1.87 million per patient. Not all of this $1.87 million will accrue to BLUE. Around $400000 will be the costs necessary for an institution to administer it. Then there are expenses that BLUE will have to bear for tailoring the drug to the patient. What’s left will be shared by the institution and BLUE.
  • Y
    YR
    In 2019 alone only 5 Bluebird executives devoured over $96,000,000 in compensation. The company does not share the price with hospitals. Production costs for Zynteglo, today is $130-200,000 per patient depending on weight. This price will come down steadily with time. The correct price is what the market will pay. European countries do not have the same health costs as the US. Convincing Germany to pay the full price is a result mostly of the fact that Germany has very few patients. Other European countries, such as Italy and Greece will not pay anything near that price. The average age of Thalassemic patients in Europe because of testing is in the late 20’s. A compliant patient in Europe costs 10-30k per year to the government. It makes some sense to pay 5-700k, assuming that they will achieve normal life spans. Trump is attempting to pass a law which says that the US will not pay more than its European counterparts for therapies. To convince Italy and Greece, the countries with the largest Thalassemic populations to pay, at least $1,000,000 will need to be shaved. The proof of this is that the product was partially approved over a year ago and not a patient has been treated. It’s very similar to the Glybera story. Glybera, was $1,200,000 per patient, one patient was treated and then the product was discontinued. At 5-700k, with the Bluebird management strategy, funds and executives pocketing as much research funds as possible (Mr. Leschly alone, has over $100,000,000 in compensation) the cost of production and company overhead makes the product a borderline loser.
  • s
    soccerfool
    Hope we head to $60+ in the next few days.....
    Bullish
  • s
    soccerfool
    so, another Saturday morning.....and reading anything on BLUE. Bottom line, it seems every time BLUE releases news, it is pretty positive. On the other hand, most "research reports," seem to say "blue is good, but has no revenue and risk,' and then goes on to recommend or tout another stock that is "better," primarily due to revenue.

    Also, insiders have NOT been buying any shares. In fact, only selling...as they have cut their own pay, and are selling shares to compensate for their decreased salaries.

    so, we either wait for revenue, or a buy out....

    institutional ownership is strong, but until retail investors see value or a risk reward proposition that is attractive we wallow in these lower levels.

    tough...since we were at $240 a couple years ago.

    good luck longs....
    Neutral
  • A
    Anonymous
    BLM hates advancement of society and yet BLUE is trying to save their lives,,,but still can't
    rally.
  • K
    Kirk
    Immunomedics takeover at over $88, current price $43 shows once again that the companies want oncology solutions
  • M
    Max
    Looking at the chart, the stock made a low of $38.95 on 3/15/20, It's not uncommon for stocks to try to retest those lows 6 months later. So, I'm thinking we'll see the low of the move sometime in the next two and a half weeks. I think it could be $48. But I won't be surprised to see $38. I'll bite at $48 and scale in to complete my position if it goes lower.

    The downtrend line that starts on 3/11/18 is about to run out of room on the time dimension. Sometime between now and the end of the year, the stock will enter a new technical phase. It's most likely going to be some sort of consolidation phase between $40 and $70. But that should set us up for a real move mid-2021 if we get some positive news. Any break above $79 will be a bullish indicator.

    My two cents FWIW.
  • z
    zzz
    This was once 229/sh. Great stock! Still waiting for this thing to go back up. I have this thing since 2015 and short puts at lower strike prices each time when close my positions. This is the most disappointing stock I ever owned.
  • L
    LongAndStrong
    Feel like a strong push to $20 #blue skies
  • a
    alex
    RIP blue
  • L
    LongAndStrong
    NIO $21 easy today , $50 EOY , may up my target if I get some more little caeser pizzas #blue skies
  • M
    Mark
    I have been trimming this stock and never made money on it. Ready to sell remaining, but my gut tells me to stick around. My gut is not a strategy. Lol. Just seems so much potential with pipeline, etc and all this does is go no where but down.
  • s
    steven
    CEO needs to be run out and investigated.
  • V
    VirginiaLova
    Oppenheimer just upgraded stock to buy with $110 price target. Avg analyst target is $97 ... any day now ...
  • B
    Bee
    Baby are you down down down down down, down, down
    Even if the sky is falling down, down, down
  • M
    Max
    Classic. Stock can't go up during an historic rise in the market but manages to go down in sympathy.